Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s traded shares stood at 0.71 million during the last session, with the company’s beta value hitting 1.26. At the close of trading, the stock’s price was $60.33, to imply an increase of 2.29% or $1.35 in intraday trading. The ARWR share’s 52-week high remains $93.66, putting it -55.25% down since that peak but still an impressive 26.59% since price per share fell to its 52-week low of $44.29. The company has a valuation of $6.27B, with an average of 0.49 million shares in intraday trading volume over the past 10 days and average of 573.70K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Arrowhead Pharmaceuticals Inc. (ARWR), translating to a mean rating of 2.20. Of 11 analyst(s) looking at the stock, 0 analyst(s) give ARWR a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.1.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) trade information
After registering a 2.29% upside in the last session, Arrowhead Pharmaceuticals Inc. (ARWR) has traded red over the past five days. The stock hit a weekly high of 62.40 this Friday, 10/08/21, jumping 2.29% in its intraday price action. The 5-day price performance for the stock is -3.63%, and -7.60% over 30 days. With these gigs, the year-to-date price performance is -21.37%. Short interest in Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) saw shorts transact 3.48 million shares and set a 3.22 days time to cover.
Analysts on Wall Street suggest a consensus price target of $86.82, implying an increase of 30.51% to the stock’s current value. The extremes give us $44.00 and $106.00 for target low and target high price respectively. As such, ARWR has been trading -75.7% off suggested target high and 27.07% from its likely low.
Arrowhead Pharmaceuticals Inc. (ARWR) estimates and forecasts
Revenue is forecast to grow 79.20% this quarter before falling -135.00% for the next one. The rating firms project that company’s revenue will grow 78.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is $56.77 million. Meanwhile, for the quarter ending Dec 2021, a total of 4 analyst(s) estimate revenue growth to $28.16 million.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 12.10% for the past 5-year period. While 2021 is set for a -221.80% return in earnings, projections for the next 5 years are at 7.33% annually.
Arrowhead Pharmaceuticals Inc. has its next earnings report out between November 22 and November 26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Arrowhead Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s Major holders
Arrowhead Pharmaceuticals Inc. insiders hold 3.18% of total outstanding shares, with institutional holders owning 65.64% of the shares at 67.80% float percentage. In total, 65.64% institutions holds shares in the company, led by Blackrock Inc. As of Jun 29, 2021, the company held over 12.15 million shares (or 11.65% of shares), all amounting to roughly $1.01 billion.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 9.64 million shares, or about 9.25% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $798.31 million.
We also have Invesco Global Opportunities Fund and iShares Core S&P Midcap ETF as the top two Mutual Funds with the largest holdings of the Arrowhead Pharmaceuticals Inc. (ARWR) shares. Going by data provided on Apr 29, 2021, Invesco Global Opportunities Fund holds roughly 3.0 million shares. This is just over 2.88% of the total shares, with a market valuation of $218.28 million. Data from the same date shows that the other fund manager holds a little less at 2.8 million, or 2.68% of the shares, all valued at about 231.6 million.